Table 3.

Safety of AZL‐M and ACE Inhibitors During 1 Year of Follow‐Up

	Newly Diagnosed Hypertension (n=1153)	Established Hypertension (n=1929)	P Value	AZL‐M (Newly Diagnosed) (n=789)	ACE Inhibitor (Newly Diagnosed) (n=364)	P Value
Patients without an AE, %	93.5	92.7	.40	92.8	95.1	.14
Patients with an AE, %	6.5	7.3	.40	7.2	4.9	.14
Laboratory values
∆ HbA1c, %	0.00±0.87	0.04±0.99	.76	0.04±0.91	−0.11±0.78	.20
∆ Fasting glucose, mg/dL	3.34±76.62	2.07±19.28	<.05	5.84±90.74	−2.54±18.59	.75
∆ Creatinine, mg/dL	0.05±0.19	−0.06±0.98	.18	0.06±0.19	0.03±0.19	.51
∆ Potassium, mmol/L	0.02±0.48	0.03±0.48	.86	0.01±0.45	0.05±0.56	.60
∆ eGFR, mL/min/1.73‐m2	−2.41±10.85	−0.92±13.53	.11	−2.91±10.37	−1.26±11.89	.67

Abbreviations: AE, adverse event; ACE, angiotensin‐converting enzyme; AZL‐M, azilsartan medoxomil; eGFR, estimated glomerular filtration rate; HbA_1c, glycated hemoglobin.